Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RDHL 
Redhill Biopharma Ltd (RDHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19000
1 Year Target Price $19000
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.29% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.06M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 1 | Beta 4.24 | 52 Weeks Range 1.06 - 11.07 | Updated Date 09/17/2025 |
52 Weeks Range 1.06 - 11.07 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual -2.29 |
Profitability
Profit Margin -97.52% | Operating Margin (TTM) -107.33% |
Management Effectiveness
Return on Assets (TTM) -25.32% | Return on Equity (TTM) -1708.61% |
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value 2409382 | Price to Sales(TTM) 0.53 |
Enterprise Value 2409382 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 0.25 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 3329860 | Shares Floating 16654500537 |
Shares Outstanding 3329860 | Shares Floating 16654500537 | ||
Percent Insiders - | Percent Institutions 2.69 |
Upturn AI SWOT
Redhill Biopharma Ltd
Company Overview
History and Background
Redhill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. Founded in 2009, Redhill has focused on acquiring and developing late-stage clinical products. Key milestones include the FDA approvals of Movantik (partnered with AstraZeneca), Talicia, and Aemcolo.
Core Business Areas
- Gastrointestinal Diseases: Focuses on developing and commercializing therapies for gastrointestinal diseases, including H. pylori infection and Crohn's disease.
- Infectious Diseases: Focuses on developing and commercializing therapies for infectious diseases, including COVID-19.
Leadership and Structure
The leadership team includes key executives in R&D, finance, and commercial operations. The organizational structure is typical of a publicly traded biopharmaceutical company, with departments focusing on research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Talicia (amoxicillin, omeprazole, and rifabutin): A fixed-dose combination antibacterial drug for the treatment of Helicobacter pylori (H. pylori) infection. Market share information is not readily available. Competitors include other combination therapies and individual antibiotics used to treat H. pylori.
- Aemcolo (rifamycin): A rifamycin antibiotic for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli. Market share information is not readily available. Competitors include other antibiotics used to treat travelers' diarrhea.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving. It is characterized by significant R&D investments, lengthy regulatory approval processes, and strong intellectual property protection.
Positioning
Redhill Biopharma focuses on niche markets within gastrointestinal and infectious diseases. Its competitive advantages include its portfolio of approved products and late-stage clinical candidates.
Total Addressable Market (TAM)
TAM for gastrointestinal and infectious disease therapeutics is substantial (billions USD). Redhill Biopharma targets specific segments within these markets with its approved products and pipeline.
Upturn SWOT Analysis
Strengths
- Approved products (Talicia, Aemcolo)
- Late-stage clinical pipeline
- Experienced management team
- Focus on niche markets
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on key products
- Dependence on regulatory approvals
- Small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships
- Acquisition of complementary assets
- Increased market penetration for existing products
Threats
- Competition from larger pharmaceutical companies
- Generic competition
- Clinical trial failures
- Regulatory changes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- MRK
- PFE
- VTRS
Competitive Landscape
Redhill Biopharma faces significant competition from larger pharmaceutical companies with greater resources and broader product portfolios. Redhill focuses on niche markets but must navigate a competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product approvals and commercialization efforts. However, revenue has not been consistent due to multiple factors.
Future Projections: Future growth projections depend on the successful development and commercialization of pipeline products. Analyst estimates should be reviewed for guidance.
Recent Initiatives: Recent initiatives include clinical trials for pipeline candidates and commercialization efforts for approved products.
Summary
Redhill Biopharma is a biopharmaceutical company with approved products in gastrointestinal and infectious diseases. The company faces challenges due to limited financial resources and strong competition. The approved products (Talicia and Aemcolo) and clinical pipeline are strengths. Future success depends on successful development and commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Redhill Biopharma Ltd. SEC Filings (10-K, 10-Q)
- Company Website
- Third-party financial data providers (e.g., Yahoo Finance, Google Finance)
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data may be estimates. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 35 | Website https://www.redhillbio.com |
Full time employees 35 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.